Sort
10,766 grants matching “checkpoint inhibitor”
Core B: Animal Model and Immunotyping Core
$384,934Thomas Alan Hamilton · Cleveland Clinic Lerner Com-Cwru · P01 · FY2023 · CA
Mouse Models of Tumor Progression and Therapy Response
$384,925Fred Hutchinson Cancer Research Center · R01 · FY2005 · CA
Mouse Models of Tumor Progression and Therapy Response
$384,925Fred Hutchinson Cancer Research Center · R01 · FY2004 · CA
Mouse Models of Tumor Progression and Therapy Response
$384,925Fred Hutchinson Cancer Research Center · R01 · FY2003 · CA
Role of Nuclear Pore-Regulated Mechanisms in Prostate Cancer Aggressiveness
$384,875Veronica Rodriguez-Bravo · Mayo Clinic Rochester · R01 · FY2023 · CA
Identifying novel therapies targeting Merkel cell carcinoma and tumor microenvironment
$384,870Ling Gao · Southern California Inst For Res/Educ · R01 · FY2022 · CA
Identifying novel therapies targeting Merkel cell carcinoma and tumor microenvironment
$384,870Ling Gao · Southern California Inst For Res/Educ · R01 · FY2025 · CA
Single-Cell, Spatial and Functional Dissection of Cancer Cell States, Co-Evolving Ecosystems, and Vulnerabilities During Tumor Progression and Metastasis
$384,868Benjamin Izar · Columbia University Health Sciences · U54 · FY2023 · CA
Integration of neo-antigen vaccines and immune checkpoint therapy
$384,650Elizabeth Marion Jaffee · Johns Hopkins University · P01 · FY2022 · CA
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)
$384,580Noah M Hahn · Johns Hopkins University · R01 · FY2021 · CA
Transcriptional and epigenetic mechanisms of immunotherapy resistance in melanoma
$384,559Kai W Wucherpfennig · Massachusetts General Hospital · P01 · FY2019 · CA
Antitumor-Antibiotics from Marine Microorganisms
$384,546William Fenical · University Of California, San Diego · R37 · FY2009 · CA
Antitumor-Antibiotics from Marine Microorganisms
$384,546William Fenical · University Of California, San Diego · R37 · FY2010 · CA
Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition
$384,278Zachary Scott Morris · University Of Wisconsin-Madison · P01 · FY2023 · CA
Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition
$384,278Zachary Scott Morris · University Of Wisconsin-Madison · P01 · FY2022 · CA
PD-1/PD-L1 signaling at the interface between immune and stem cell crosstalk
$384,250Melissa L Harris · University Of Alabama At Birmingham · R56 · FY2025 · AI
E2A AS A POTENTIAL TUMOR SUPPRESSOR
$384,245Cornelis Murre · University Of California, San Diego · R01 · FY2008 · CA
RNase H2 is a novel therapeutic target in triple negative breast cancer
$384,115Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
RNase H2 is a novel therapeutic target in triple negative breast cancer
$384,115Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
MAIT cells as a therapeutic approach for gastrointestinal cancers
$384,092Daniel Ted Leung · University Of Utah · R21 · FY2024 · CA
Covalent Protein Binders for Cancer Research and Therapy
$384,009Lei Wang · University Of California, San Francisco · R01 · FY2024 · CA
Engineering Nanomaterials to Prime Immunity
$383,908James J. Moon · University Of Michigan At Ann Arbor · R01 · FY2019 · CA
Mechanism of Mitotic Checkpoint in Mammalian Cells
$383,900Timothy Yen · Research Inst Of Fox Chase Can Ctr · R01 · FY2009 · GM
(PQC2) Plasticity Of The.PI3K Network In Early Dormancy
$383,875Dario C. Altieri · Wistar Institute · R01 · FY2014 · CA
(PQC2) Plasticity Of The.PI3K Network In Early Dormancy
$383,875Dario C. Altieri · Wistar Institute · R01 · FY2015 · CA